Endocrine research · 2025
Change in apnea hypopnea index and sleep quality following treatment in acromegaly.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kadian Kavita, Gupta Ravi, Arora Rajnish, Sridharan Kalyani
Аннотация
BACKGROUND: Sleep Apnea Syndrome (SAS) is a common problem in acromegaly. This study examines changes in apnea hypopnea index (AHI) and sleep quality following treatment for acromegaly.
METHODS: Subjects with active acromegaly underwent polysomnography to identify SAS and Pittsburgh Sleep Quality Index (PSI) questionnaire for the assessment of subjective sleep quality at baseline, which were repeated after treatment.
RESULTS: Twenty patients were recruited. Obstructive SAS was present in 85% and poor sleep quality was reported in 65% patients. AHI positively correlated with age, duration of disease, male gender, and PSQI score. After treatment, there was a significant decrease in tumor volume (72%) and insulin-like growth hormone (IGF-1) levels (44%), although IGF-1 normalization was seen in only 34% subjects. There was a significant reduction in mean AHI (35 ± 20 vs 23 ± 19; p = 0.008) and mean PSQI (7.8 ± 3.9 vs 5.6 ± 3.6; p = 0.002) after treatment.
CONCLUSION: Mean AHI and mean PSQI improved significantly after treatment, although normalization of IGF-1 was seen in only one-third of patients.
METHODS: Subjects with active acromegaly underwent polysomnography to identify SAS and Pittsburgh Sleep Quality Index (PSI) questionnaire for the assessment of subjective sleep quality at baseline, which were repeated after treatment.
RESULTS: Twenty patients were recruited. Obstructive SAS was present in 85% and poor sleep quality was reported in 65% patients. AHI positively correlated with age, duration of disease, male gender, and PSQI score. After treatment, there was a significant decrease in tumor volume (72%) and insulin-like growth hormone (IGF-1) levels (44%), although IGF-1 normalization was seen in only 34% subjects. There was a significant reduction in mean AHI (35 ± 20 vs 23 ± 19; p = 0.008) and mean PSQI (7.8 ± 3.9 vs 5.6 ± 3.6; p = 0.002) after treatment.
CONCLUSION: Mean AHI and mean PSQI improved significantly after treatment, although normalization of IGF-1 was seen in only one-third of patients.